Curbstone Financial Management Corp Buys 400 Shares of Danaher Co. (NYSE:DHR)

Curbstone Financial Management Corp raised its stake in shares of Danaher Co. (NYSE:DHR) by 11.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,966 shares of the conglomerate’s stock after acquiring an additional 400 shares during the period. Curbstone Financial Management Corp’s holdings in Danaher were worth $813,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Heck Capital Advisors LLC bought a new position in shares of Danaher during the fourth quarter valued at about $27,000. Golden State Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter valued at about $31,000. Hurley Capital LLC bought a new position in shares of Danaher during the fourth quarter valued at about $34,000. Pineridge Advisors LLC lifted its position in shares of Danaher by 63.3% during the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares in the last quarter. Finally, Rialto Wealth Management LLC bought a new position in shares of Danaher during the fourth quarter valued at about $34,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the business’s stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares of the company’s stock, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

DHR stock opened at $202.63 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a one year low of $171.00 and a one year high of $281.70. The stock has a market cap of $145.02 billion, a PE ratio of 38.38, a P/E/G ratio of 2.66 and a beta of 0.77. The firm has a 50 day simple moving average of $191.32 and a two-hundred day simple moving average of $211.72.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.58 billion. On average, analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.63%. Danaher’s payout ratio is 24.85%.

Analyst Ratings Changes

A number of research firms recently weighed in on DHR. Argus dropped their price target on shares of Danaher from $260.00 to $240.00 in a research report on Wednesday, April 23rd. Wells Fargo & Company dropped their price target on shares of Danaher from $240.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 23rd. JPMorgan Chase & Co. lowered their price objective on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 22nd. Citigroup reaffirmed a “buy” rating on shares of Danaher in a research report on Monday, April 7th. Finally, Wolfe Research lowered their price objective on shares of Danaher from $275.00 to $220.00 and set an “outperform” rating on the stock in a research report on Monday, April 7th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $248.17.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.